Scopus BioPharma Inc.
SCPS
$0.0003
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -64.95% | -75.05% | -82.92% | -63.42% | 54.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.77% | -42.51% | -71.84% | -31.21% | -78.28% |
| Operating Income | 11.77% | 42.51% | 71.84% | 31.21% | 78.28% |
| Income Before Tax | 11.77% | 42.51% | 71.84% | -35.59% | 78.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.77% | 42.51% | 71.84% | -35.59% | 78.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.18% | 47.44% | 73.45% | -35.59% | 78.76% |
| EBIT | 11.77% | 42.51% | 71.84% | 31.21% | 78.28% |
| EBITDA | 11.77% | 42.50% | 71.84% | 31.21% | 78.28% |
| EPS Basic | 58.20% | 63.47% | 75.62% | -10.16% | 83.69% |
| Normalized Basic EPS | 61.18% | 65.53% | 76.53% | -10.39% | 83.69% |
| EPS Diluted | 58.20% | 63.47% | 75.62% | -10.16% | 83.69% |
| Normalized Diluted EPS | 61.18% | 65.53% | 76.53% | -10.39% | 83.69% |
| Average Basic Shares Outstanding | 88.40% | 43.97% | 8.98% | 23.01% | 30.28% |
| Average Diluted Shares Outstanding | 88.40% | 43.97% | 8.98% | 23.01% | 30.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |